Vertex Announces First Quarter 2022 Financial Results
View our 2021 Corporate Responsibility Report
Read more about how we continued to operate as a responsible business, supported our communities and drove lasting social and environmental change in 2021.
Pain Program Update
We’ve announced Phase 2 data from two studies of an investigational small molecule for the potential treatment of acute pain.
Kidney Disease Program Update
Our APOL1-mediated kidney disease program moves into pivotal development
Type 1 Diabetes Program Update
We’ve announced new data for the ongoing Phase 1/2 study of our investigational cell therapy program for the treatment of type 1 diabetes (T1D).